v3.26.1

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Revenue:
Total revenue	$ 5,023	$ 3,439
Operating expenses:
Cost of product revenue	544	423
Cost of license and collaboration revenue	345	14
Selling, general and administrative	9,989	8,848
Research and development	3,860	2,284
Total operating expenses	14,738	11,569
Loss from operations	(9,715)	(8,130)
Other income (expense):
Interest income	201	337
Interest expense	(160)	(2,203)
Change in fair value of derivative liability	0	254
Other expense	(8)	0
Total other income (expense), net	33	(1,612)
Net loss	$ (9,682)	$ (9,742)
Net loss per share, basic (in dollars per share)	$ (0.45)	$ (1.03)
Net loss per share, diluted (in dollars shares)	$ (0.45)	$ (1.03)
Weighted-average common shares outstanding, basic (in shares)	21,305,025	9,483,734
Weighted-average common shares outstanding, diluted (in shares)	21,305,025	9,483,734
Product revenue, net
Revenue:
Total revenue	$ 4,290	$ 3,422
License and collaboration revenue
Revenue:
Total revenue	$ 733	$ 17

Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-SubTopic 10
-Topic 825
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482881/825-10-55-10

Verrica Pharmaceuticals Inc. 10-Q